155
Views
3
CrossRef citations to date
0
Altmetric
Original Articles

Severe Hypotony Maculopathy in Anterior Uveitis Associated with Hodgkin Lymphoma

, MD, FEBO, , MD, FEBO, , MD, , MD, FEBOORCID Icon, , MD, FEBOORCID Icon & , MD
Pages 460-464 | Received 28 Jul 2019, Accepted 12 Sep 2019, Published online: 24 Oct 2019

References

  • Metzger ML, Mauz-Korholz C. Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma. Br J Haematol. 2019;185:1142–1157. doi:10.1111/bjh.15789.
  • Thomas RK, Re D, Zander T, Wolf J, Diehl V. Epidemiology and etiology of Hodgkin’s lymphoma. Ann Oncol. 2002;13(Suppl 4):147–152. doi:10.1093/annonc/mdf652.
  • Mosteller MW, Margo CE, Hesse RJ. Hodgkin’s disease and granulomatous uveitis. Ann Ophthalmol. 1985;17:787–790.
  • Towler H, de la Fuente M, Lightman S. Posterior uveitis in Hodgkin’s disease. Aust N Z J Ophthalmol. 1999;27:326–330.
  • Barkana Y, Zadok D, Herbert M, Kornberg A, Nemet P. Granulomatous kerato-conjunctivitis as a manifestation of Hodgkin lymphoma. Am J Ophthalmol. 2001;131:796–797. doi:10.1016/s0002-9394(00)00895-3.
  • Mateo-Montoya A, Bonnel S, Wolff B, Heron E, Sahel JA. White dots in the eye fundus revealing Hodgkin’s lymphoma. Eye (Lond). 2010;24:934–937. doi:10.1038/eye.2009.188.
  • Brihaye-Van Geertruyden M. Retinal lesions in Hodgkin’s disease. AMA Arch Ophthalmol. 1956;56:94–99.
  • Barr CC, Joondeph HC. Retinal periphlebitis as the initial clinical finding in a patient with Hodgkin’s disease. Retina. 1983;3:253–257. doi:10.1097/00006982-198300340-00003.
  • Thomas M, Vajaranant TS, Aref AA. Hypotony maculopathy: clinical presentation and therapeutic methods. Ophthalmol Ther. 2015;4:79–88. doi:10.1007/s40123-015-0037-z.
  • Arevalo JF, Garcia RA, Fernandez CF. Anterior segment inflammation and hypotony after posterior segment surgery. Ophthalmol Clin North Am. 2004;17:527–537,vi. doi:10.1016/j.ohc.2004.06.004.
  • Daniel E, Pistilli M, Pujari SS, et al. Risk of hypotony in noninfectious uveitis. Ophthalmology. 2012;119:2377–2385. doi:10.1016/j.ophtha.2012.05.032.
  • Roe R, Branco BC, Cunningham ET Jr. Hypotony maculopathy in a patient with HLA-B27-associated uveitis. Ocul Immunol Inflamm. 2008;16:107–108. doi:10.1080/09273940802023794.
  • Dutta Majumder P, Burugupalli K, Menia NK, Ganesh SK, Biswas J. Pattern of uveitic hypotony in a tertiary eye hospital in India. Ocul Immunol Inflamm. 2018;26:924–928. doi:10.1080/09273948.2017.1294183.
  • Kapur R, Birnbaum AD, Goldstein DA, et al. Treating uveitis-associated hypotony with pars plana vitrectomy and silicone oil injection. Retina. 2010;30:140–145. doi:10.1097/IAE.0b013e3181b32f06.
  • de Smet MD, Gunning F, Feenstra R. The surgical management of chronic hypotony due to uveitis. Eye (Lond). 2005;19:60–64. doi:10.1038/sj.eye.6701425.
  • Primbs GV, Monsees WE, Irvine AR Jr. Intraocular Hodgkin’s disease. Arch Ophthalmol. 1961;66:477–482. doi:10.1001/archopht.1961.00960010479007.
  • Gupta P, Gupta A, Gupta V, Singh R. Successful outcome of pars plana vitreous surgery in chronic hypotony due to uveitis. Retina. 2009;29:638–643. doi:10.1097/IAE.0b013e31819a5fd8.
  • Accorinti M, Ciapparoni V, Pirraglia MP, Pivetti-Pezzi P. Treatment of severe ocular hypotony in AIDS patients with cytomegalovirus retinitis and cidofovir-associated uveitis. Ocul Immunol Inflamm. 2001;9:211–217.
  • Pivetti-Pezzi P, Da Dalt S, La Cava M, Pinca M, De Gregorio F, Virno M. Ibopamine treatment in chronic hypotony secondary to long-lasting uveitis. A case report. Eur J Ophthalmol. 2000;10:332–334.
  • Ugahary LC, Ganteris E, Veckeneer M, et al. Topical ibopamine in the treatment of chronic ocular hypotony attributable to vitreoretinal surgery, uveitis, or penetrating trauma. Am J Ophthalmol. 2006;141:571–573. doi:10.1016/j.ajo.2005.09.034.
  • Ganteris-Gerritsen E, Ugahary LC, Jansen J, Mulder PG, Cohen AF, van Meurs JC. Six months treatment with ibopamine in patients with hypotony after vitreoretinal surgery for retinal detachment, uveitis or penetrating trauma. Retina. 2012;32:742–747. doi:10.1097/IAE.0b013e3182265177.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.